We are live on ! Find out more
CLRBW

Cellectar Biosciences, Inc.
CLRBW

Delisted

CLRBW was delisted on the 20th of August, 2019.

Back to rankings

4 hedge funds and large institutions have $7K invested in Cellectar Biosciences, Inc. in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% less funds holding

Funds holding: 5 → 4 (-1)

46% less capital invested

Capital invested by funds: $13K → $7K (-$6K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$28
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$4K – – –
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$3K -$28 -180 -0.6%

CLRBW Hedge Fund Activity: Q3 2018 in Review

4 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences, Inc. (CLRBW) for Q3 2018, worth a combined $7K — down 46% from $13K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CLRBW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest seller was Susquehanna International Group, cutting an estimated $28.

  • 4 institutional investors held Cellectar Biosciences, Inc. (CLRBW) as of Q3 2018, down from 5 in Q2 2018.
  • Funds reported $7K of Cellectar Biosciences, Inc. stock for Q3 2018, down 46% quarter-over-quarter.
  • 0 funds opened new Cellectar Biosciences, Inc. positions in Q3 2018 and 1 closed out, a net change of -1 holder.
  • The largest Cellectar Biosciences, Inc. seller in Q3 2018 was Susquehanna International Group, an estimated $28 sold.

Based on aggregated 13F filings for Q3 2018.